The present invention relates to a CHO cell-derived protein secretory factor, an expression cassette in which a nucleic acid sequence encoding the protein secretory factor; and a gene encoding a target protein are operably linked, an expression vector comprising the expression cassette, a transformed cell into which the expression vector is introduced, and a method for producing a target protein using the transformed cell.

A method and a mineral wool product include a multiple of lamellae, such as a sandwich panel core. The product includes a plurality of lamellae cut from a mineral wool web, and bonded together by applying an adhesive on the surfaces of two adjacent lamellae to form a web-like product, wherein the adhesive comprises at least one hydrocolloid.

A method and a mineral wool product include a multiple of lamellae, such as a sandwich panel core. The product includes a plurality of lamellae cut from a mineral wool web, and bonded together by applying an adhesive on the surfaces of two adjacent lamellae to form a web-like product, wherein the adhesive comprises at least one hydrocolloid.

A method of bonding together surfaces of two or more elements. The method includes the steps of providing two or more elements, applying an adhesive to one or more of the surfaces to be bonded together before, during or after contacting the surfaces to be bonded together with each other, and curing the adhesive, wherein the adhesive comprises at least one hydrocolloid.

The invention relates to an aqueous binder composition for mineral fibers comprising at least one polyelectrolytic hydrocolloid.

A method for setting a threshold for basal levels of QSOX1-L in urine comprising: Storing de-identified urine from 100 BC patient samples and from 100 patients with non-malignant conditions; serially diluting the patient samples with a blocking buffer in triplicate followed by incubation in ELISA plates coated with anti-QSOX-L capture Ab; after 1-hour incubation at 37 C, washing plates followed by addition of biotinylated anti-QSOX-L detection antibody; using Streptavidin-HRP to generate dose dependent signal; obtaining a standard curve for each plate using recombinant QSOX1-L protein spiked into urine that has been depleted of QSOX1-L using affinity chromatography column conjugated with anti-sera against 100aa peptide; calculating concentrations of QSOX1-L based on a standard curve for each plate; and calculating a mean concentrations, ±2 SD to establish a reference range for QSOX1-L levels in urine from patients and individuals without malignant disease.

The present invention relates to a method of producing a coherent growth substrate product formed of man-made vitreous fibres (MMVF), comprising the steps of (vi) providing MMVF; (vii) providing an uncured binder composition; (viii) providing a superabsorbent polymer; (ix) forming a mixture of the MMVF, the uncured binder composition and the superabsorbent polymer; (x) curing the uncured binder composition in the mixture to form the coherent growth substrate product; wherein the uncured binder composition comprises at least one hydrocolloid.

The present invention relates to products and processes for the treatment or prevention of viral infection(s). In particular the invention relates to the use of one or more proteins, typically obtained from milk, for the treatment or prevention of viral infection(s). In particular embodiments the invention uses combinations of milk proteins for the treatment or prevention of viral infection(s). The products of the invention may be used in combination with other active agents, including other antiviral agents.

A formaldehyde-free binder composition for mineral fibers which comprises at least one phenol containing compound and at least one protein.

An aqueous binder composition for mineral fibers which comprises at least one polyelectrolytic hydrocolloid.